The trial is designed to evaluate the safety and efficacy of the combination in patients with refractory diffuse large B-cell lymphoma (DLBCL). PD-L1 expression in DLBCL is associated
DPP1 is an enzyme that catalyzes the activation of neutrophil serine proteases (NSPs), which play a key role in pulmonary diseases such as non-cystic fibrosis bronchiectasis (non-CF bronchiectasis).
Codexis will receive an $8 million payment from Merck for completion of this milestone to be paid in the fourth quarter of 2016. Codexis President and CEO John
Solabegron is a highly potent and selective beta-3 adrenoceptor agonist that is being developed for the treatment of overactive bladder (OAB). Moreover, solabegron has already demonstrated efficacy for
TD-1473 is a novel, potent, orally administered and intestinally restricted pan-Janus kinase (JAK) inhibitor in clinical development, with the potential to treat a range of inflammatory intestinal diseases.
Under terms of the agreement, Daiichi Sankyo and AgonOx will collaborate on preclinical development of the program. Following preclinical assessment, Daiichi Sankyo has an exclusive option to research,
The deal grants Sarepta rights in Europe, as well as in Turkey and the Commonwealth of Independent States (‘the licensed territory’), to Summit’s utrophin modulator pipeline, including its lead
The $12.9m Series A round of funding was led by leading deep technology investor Lux Capital, with participation from Obvious Ventures, Epic Ventures, Data Collective, AME Cloud Ventures, Wild
The EC has also approved the transfer of the orphan designation to Sobi. As MAH, Sobi will assume full regulatory responsibility for Alprolix in the EU. The EC
Osimertinib which was only licensed in February this year is recommended in draft guidance to treat a particularly aggressive form of lung cancer. Earlier this year, NICE said
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.